ImageneBio, Inc. (IMA)

Market Cap	59.22M
Revenue (ttm)	n/a -77.1%
Net Income	-53.89M
EPS	-7.06
Shares Out	11.28M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	14,756
Open	5.62
Previous Close	5.65
Day's Range	5.25 - 5.63
52-Week Range	3.94 - 18.00
Beta	n/a
Analysts	Buy
Price Target	13.00 (+147.62%)
Earnings Date	May 7, 2026

About IMA

ImageneBio, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for patients with immunological, autoimmune and inflammatory diseases. Its lead product candidate includes IMG-007, a non-depleting anti-OX40 monoclonal antibody that binds to OX40 receptor on activated T cells to block receptor binding to OX40 ligand which is in Phase 1b/2a clinical trial. The company was formerly known as Ikena Oncology, Inc. and changed its name to ImageneBio, Inc. in July 2025. ImageneBio, Inc. is headquartered in San Diego, California.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2019
• Employees: 15
• Stock Exchange: NASDAQ
• Ticker Symbol: IMA
• Website: https://www.inmagenebio.com

Financial Performance

In 2025, ImageneBio's revenue was $800,000, a decrease of -77.14% compared to the previous year's $3.50 million. Losses were -$52.40 million, 8.29% more than in 2024.

Analyst Summary

According to 3 analysts, the average rating for IMA stock is "Buy." The 12-month stock price target is $13.0, which is an increase of 147.62% from the latest price.

Price Target

$13.0

(147.62% upside)

Analyst Consensus: Buy